Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Wolverhampton
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Wolverhampton, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2864 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 16 Oct 2026, 03:15 UTC
2864
Studies in scope
industry-sponsored, all four open statuses
1382
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2023 Manchester 667 Birmingham 480 Glasgow 437 Cambridge 425
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Janssen Research & Development, LLC7 Hoffmann-La Roche4 AstraZeneca4 AbbVie3 GlaxoSmithKline3
Site city
London2023 Manchester667 Birmingham480 Glasgow437 Cambridge425
All 429 cities
Target enrolment
to

Trials with a site in Wolverhampton

49 of 2864 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
Hoffmann-La Roche
Phase 3
380
London, Oxford, Wolverhampton
2026-06-23
Recruiting
Altesa Biosciences, Inc.
Phase 2
180
Bromborough, Glasgow, London, Milton Keynes, Wolverhampton
2026-05-01
Recruiting
Janssen Research & Development, LLC
Phase 3
530
Greater London, Iselworth, London, Norwich, Wolverhampton
2026-04-21
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
Cambridge, London, Chelsea, Sutton, Stoke-on-Trent, Nottingham, Wolverhampton
2025-11-30
Recruiting
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269Geographic Atrophy Secondary to Age-related Macular Degeneration
ADARx Pharmaceuticals, Inc.
Phase 2
240
Liverpool, Dorchester, Wolverhampton, London, Sunderland
2025-11-10
Recruiting
Bristol-Myers Squibb
Observational
223
Oxford, Bath, Wolverhampton, London
2025-10-08
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 2/3
176
Derby, Doncaster, Edinburgh, London, Wolverhampton
2025-09-30
Recruiting
AbbVie
Observational
2,795
London, Oxford, Leeds, Wakefield, Belfast, Cardiff, Walsall, Wolverhampton
2025-09-02
Recruiting
Pharmazz, Inc.
Phase 3
514
Bury, London, Southampton, Wolverhampton, Harrow, Newcastle, Stoke-on-Trent
2025-07-24
Active, closed
Hoffmann-La Roche
Phase 4
274
Cardiff, Leeds, Liverpool, London, Newcastle upon Tyne, Wolverhampton
2025-03-14
Active, closed
Takeda
Phase 3
601
London, Coventry, Bradford, Harlow, Stoke-on-Trent, Wolverhampton
2025-03-10
Active, closed
Immunovant Sciences GmbH
Phase 2
120
Edinburgh, London, North Shields, Wolverhampton
2025-01-10
Recruiting
Aziende Chimiche Riunite Angelini Francesco S.p.A
Observational
200
Glasgow, Wolverhampton
2024-12-19
Recruiting
GlaxoSmithKline
Phase 3
520
Leicester, Middlesbrough, Oxford, Plymouth, Wolverhampton
2024-12-16
Active, closed
MoonLake Immunotherapeutics AG
Phase 3
600
Westcliff-on-Sea, Barnet, Leeds, Wolverhampton
2024-10-15
Recruiting
AbbVie
Phase 2
590
Edinburgh, Glasgow, London, Oxford, Coventry, Wolverhampton, Bristol, Cardiff
2024-09-04
Recruiting
Jazz Pharmaceuticals
Phase 3
550
Bath, Glasgow, Leicester, London, Manchester, Oxford, Wolverhampton
2024-08-13
Active, closed
EyeBiotech Ltd.
Phase 2/3
984
London, York, Bradford, Bristol, Liverpool, Sunderland, Wolverhampton
2024-08-07
Active, closed
Novartis Pharmaceuticals
Phase 3
162
Barnet, Wolverhampton
2024-06-28
Recruiting
AstraZeneca
Phase 3
240
Edinburgh, London, Wolverhampton
2024-06-20
Recruiting
Neuronostics Ltd
Not applicable
559
Truro, Wolverhampton
2024-05-21
Active, closed
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease
DrugPirfenidone
Avalyn Pharma Inc.
Phase 2
375
Cottingham, Birmingham, Glenfield, London, Londonderry, Oxford, Exeter, Wolverhampton
2024-04-03
Recruiting
GlaxoSmithKline
Phase 3
864
Edinburgh, Gloucester, London, Nottingham, Sutton, Wolverhampton
2024-03-21
Recruiting
Eli Lilly and Company
Phase 3
1,264
Aberdeen, Dundee, Huddersfield, Leeds, Manchester, Northwood, Sheffield, Wolverhampton
2023-12-21
Recruiting
Janssen-Cilag Ltd.
Observational
900
Birmingham, London, Wolverhampton
2023-12-18
Recruiting
Abbott Medical Devices
Observational
1,000
London, Middlesbrough, Stoke-on-Trent, Wolverhampton
2023-09-29
Active, closed
Bristol-Myers Squibb
Phase 3
774
Southampton, Wolverhampton, Birmingham, Cannock
2023-09-11
Recruiting
Gilead Sciences
Phase 3
402
Hull, Ipswich, Leeds, London, Newcastle upon Tyne, Oxford, Sheffield, Wolverhampton
2023-09-07
Active, closed
Umecrine Cognition AB
Phase 1/2
202
Birmingham, Glasgow, London, Newcastle, Nottingham, Oxford, Portsmouth, Wolverhampton
2023-04-14
Active, closed
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
NCT05478304Ischemic Stroke, Systemic Embolism
AtriCure, Inc.
Not applicable
6,573
Sheffield, London, Middlesbrough, Wolverhampton, Cambridge
2023-01-25
Active, closed
Janssen Research & Development, LLC
Phase 3
213
Leeds, Leicester, Surrey, Wolverhampton
2022-12-15
Recruiting
Janssen Research & Development, LLC
Phase 3
1,590
Birmingham, Blackpool, Bristol, Cambridge, Canterbury, Edinburgh, London, Wolverhampton
2022-10-25
Active, closed
GlaxoSmithKline
Phase 2
351
Middlesbrough, Middlesex, Wolverhampton
2022-10-14
Active, closed
Janssen Research & Development, LLC
Phase 3
864
Blackpool, Dundee, London, Newcastle upon Tyne, Nottingham, Plymouth, Sutton, Wolverhampton
2022-10-13
Active, closed
AstraZeneca
Phase 3
341
London, Manchester, Wolverhampton
2022-08-03
Active, closed
Janssen Research & Development, LLC
Phase 2
703
Belfast, Birmingham, Cambridge, Glasgow, High Wycombe, London, Oxford, Wolverhampton
2022-07-22
Active, closed
Daiichi Sankyo
Phase 3
586
Birmingham, Glasgow, Leeds, Leicester, London, Manchester, Wolverhampton
2022-07-08
Active, closed
Pfizer
Phase 3
854
Cambridge, Birmingham, Belfast, Glasgow, Reading, Wolverhampton
2022-03-25
Active, closed
Eli Lilly and Company
Phase 3
152
London, Nottingham, Wolverhampton
2021-12-20
Active, closed
Hoffmann-La Roche
Phase 3
451
Bristol, Liverpool, London, Newcastle upon Tyne, Sunderland, Wolverhampton
2021-07-14
Active, closed
Incyte Corporation
Phase 3
899
Aberdeen, Bath, Birmingham, Bristol, London, Nottingham, Sutton, Wolverhampton
2021-05-11
Active, closed
Incyte Corporation
Phase 3
654
Birmingham, Bristol, Leicester, London, Manchester, Middlesbrough, Sutton, Wolverhampton
2021-04-15
Active, closed
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
NCT03844048Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
DrugsVenclexta·Venetoclax
AbbVie
Phase 3
165
Plymouth, Leicester, London, Southampton, Blackpool, Liverpool, Wolverhampton
2019-09-06
Active, closed
Janssen Research & Development, LLC
Phase 3
2,517
Bristol, Cardiff, Dundee, London, Preston, Sutton, Wakefield, Wolverhampton
2019-06-11
Active, closed
Acerta Pharma BV
Phase 3
984
Cambridge, Canterbury, Wolverhampton
2019-02-25
Active, closed
Janssen Research & Development, LLC
Phase 3
765
Blackburn, Lancaster, London, Torquay, Truro, Wolverhampton
2019-01-25
Recruiting
Hoffmann-La Roche
Phase 3
1,000
Bristol, Liverpool, London, Newcastle upon Tyne, Sunderland, Wolverhampton
2018-09-20
Active, closed
AstraZeneca
Phase 3
953
Guildford, London, Manchester, Metropolitan Borough of Wirral, Nottingham, Taunton, Wolverhampton
2015-11-03
Active, closed
AstraZeneca
Phase 3
510
Aberdeen, London, Manchester, Nottingham, Sutton, Wolverhampton
2013-09-25
Rows per page Showing 1–49 of 49
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 16 October 2026. https://priyalifescience.com/clinical-trials-uk/city/wolverhampton

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,864 studies in total at the last sync on 16 Oct 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 49 of those studies with a site in Wolverhampton.

How many clinical trials are recruiting in Wolverhampton?

22 of the 49 studies on this page are recruiting new participants as of the 16 Oct 2026, 03:15 UTC sync. A further 0 have not yet opened recruitment, 27 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Wolverhampton), 49 studies
PhaseStudiesRecruitingShare
Phase 3311263.3%
Phase 27314.3%
Observational5510.2%
Not applicable214.1%
Phase 2/3214.1%
Phase 1/2102%
Phase 4102%

Most active sponsors

Lead sponsors with the most studies (Wolverhampton)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC72
AstraZeneca41
Hoffmann-La Roche42
AbbVie32
GlaxoSmithKline32
Bristol-Myers Squibb21
Eli Lilly and Company21
Incyte Corporation20
Abbott Medical Devices11
Acerta Pharma BV10
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.